Bone union‐promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model
- 3 April 2024
- journal article
- research article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 42 (8) , 1831-1840
Abstract
Spinal fixation surgery has been increasingly performed in patients with osteoporosis. Romosozumab, a drug that was introduced in Japan recently, is known to possibly promote bone healing. However, few studies have reported the therapeutic effects of romosozumab in clinical practice in Japan. Therefore, here, we investigated the effects of romosozumab dosage on bone fusion promotion using an ovariectomized rat spinal fusion model. Eight‐week‐old female Sprague‐Dawley rats were matched by body weight and divided into three groups: 1.0 romosozumab (R) group (Evenity®, 25 mg/kg), 1/10R group (Evenity®, 2.5 mg/kg), and control (C) group (saline). Subcutaneous injections were administered twice a week for 8 weeks postoperatively. Computed tomography scans were performed every 2 weeks from the time of surgery till 8 weeks postoperatively. The mean fusion rates in terms of volume were significantly higher in the R groups [1/10R, 1.0R] than in the C group from 4 weeks postoperatively. The rate of increase was significantly higher in the 1.0R group from 4 weeks postoperatively and in the 1/10R group from 6 weeks postoperatively, than in the C group. The proportion of trabecular bone area was approximately 1.5 times higher in the R groups than in the C group. No significant differences were observed between the R groups. Our results suggest that romosozumab stimulates bone growth at the graft site, and similar effects were achieved at 1/10 of the standard dosage.Keywords
This publication has 39 references indexed in Scilit:
- Bone union‐promoting effect of romosozumab in a rat posterolateral lumbar fusion modelJournal of Orthopaedic Research, 2022
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumabOsteoporosis International, 2019
- Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of TreatmentJournal of Bone and Mineral Research, 2019
- Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesisJournal of Orthopaedic Research, 2017
- Sclerostin Antibody Administration Converts Bone Lining Cells Into Active OsteoblastsJournal of Bone and Mineral Research, 2016
- Single-level instrumented posterolateral fusion of the lumbar spine with a local bone graft versus an iliac crest bone graft: a prospective, randomized study with a 2-year follow-upEuropean Spine Journal, 2010
- Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bonesJournal of Bone and Mineral Research, 2010
- Union versus nonunion after posterolateral lumbar fusion: a comparison of long-term surgical outcomes in patients with degenerative lumbar spondylolisthesisEuropean Spine Journal, 2008
- Time course of vertebral osteopenia in ovariectomized ratsBone, 1989
- Histologic evidence for osteopenia and increased bone turnover in ovariectomized ratsBone, 1986